04/10/2024 -
Royalty Monetization Update
Join us for the next edition of the Life Sciences Growth Series where we'll be giving updates on royalty monetization transactions for biopharmaceutical companies.
01/18/2024 -
Medical Device Update for 2024
Join us for the 2024 kickoff of the Morgan Lewis Life Sciences Growth Series! Following the anticipated industry changes from the J.P. Morgan Healthcare Conference (JPM), this edition will analyze new trends and regulations in the medical device industry that intersect with the US Food and Drug Administration’s (FDA’s) regulation of drugs/biologics.
03/31/2022 -
Royalty Monetization Transactions
In this session, partners Andrew Mariniello and Conor Larkin will discuss the different structures employed in such transactions, describe the key issues to be considered by sellers and their investment partners, and explain how companies and inventors utilize royalty monetization transactions to raise capital.
11/10/2021 -
Founders' Agreements, Convertible Notes, and SAFEs
In this session, partner Michael Barron and associate Sheri Yano will discuss key features of founders' agreements, convertible notes, and SAFEs; whether a founders' agreement makes sense for your company; and whether a convertible note or SAFE makes sense for your company.
01/29/2021 -
Artificial Intelligence (AI) in R&D and Clinical Trials
In this session, FDA partners Kathleen Sanzo and Jacqueline Berman will explain how the biopharma industry is using AI to increase efficiencies during the drug development process, explore the legal and regulatory implications of AI’s application to clinical trials, and discuss the potential future of AI in the Food and Drug Administration’s drug and biologic divisions.
12/15/2020 -
Focus: AI in Biotech
This session will cover recent trends in the patentability of digital health innovations and the use of artificial intelligence platforms in healthcare: including Medical Imaging and Diagnostics, Advanced Healthcare Biometrics, and Drug Discovery.
12/17/2019 -
Developments in the Cell Therapy/Gene Therapy Space
From CRISPR-Cas9 to iPSCs and mRNA inhibitors, cell and gene therapies represent the cutting edge of innovation. While this exciting and rapidly developing field continues to revolutionize the pharmaceutical and biotechnology industry, it also presents unique legal and regulatory challenges. Please join us for a discussion of some of the key legal and regulatory issues impacting the cell and gene therapy space.
11/05/2019 -
University Licensing
Please join us for the next installment of the Life Sciences Growth Series, focused on university licensing. This webinar gives an overview of university licensing, what it is, the motivation behind it, and university-specific policies and laws.
05/22/2019 -
Opportunities in Food and Agricultural Tech
Recent scientific advancements have revolutionized the way food and agricultural products are being grown, sold, and regulated. Partner Robert Hibbert provides an overview of some of these advancements and what these technologies mean for the food/agricultural industry going forward.
